ReviewMolecular oncology2021
Vaccination against HPV: boosting coverage and tackling misinformation.
Review in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs.Human vaccines & immunotherapeutics · 2024Pooled it
- Tough talks COVID-19 (TT-C) digital health intervention: multistate randomized controlled trial.Scientific reports · 2025Trial
- Addressing HPV vaccine hesitancy and misinformation in India through public health communication strategies.Human vaccines & immunotherapeutics · 2026Article
- European Code Against Cancer 5th edition: 14 ways you can help prevent cancer.The Lancet regional health. Europe · 2026Review
- Transient receptor potential canonical 3 is required for HPV-induced malignant transformation of cervical epithelial cells.Communications biology · 2026Article
- Stress Disorders and Human Papillomavirus-Related Cancer Rates: A Population-Based Cohort Study in Denmark.Clinical epidemiology · 2026Article
- Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Overcoming HPV Vaccine Hesitancy in Japan: A Narrative Review of Safety Evidence, Risk Communication, and Policy Approaches.Vaccines · 2025Review
- Improving HPV Vaccine Coverage in Tennessee: Addressing Barriers and Expanding Access for Mid-Adults.Pathogens (Basel, Switzerland) · 2025Review
- Understanding PrEP misconceptions and their impact on PrEP initiation and use among pregnant and lactating women in Malawi.PLOS global public health · 2025Article
- Article
- Article
- Knowledge, Attitude, and Uptake of Human Papillomavirus (HPV) Vaccination among Chinese Female Adults: A National Cross-sectional Web-Based Survey Based on a Large E-commerce Platform.Maternal and child health journal · 2024Article
- Challenges and strategies in adolescent vaccination: Number 12 - 2024.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
- Analysis of factors influencing HPV vaccination intention among Chinese college students: structural equation modeling based on health belief theory.Frontiers in public health · 2024Article
- Parental perceptions of the HPV vaccine for prevention of anogenital and oropharyngeal cancers.Vaccine: X · 2023Article
- HPV vaccine narratives on Twitter during the COVID-19 pandemic: a social network, thematic, and sentiment analysis.BMC public health · 2023Article
- Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection.International journal of cancer · 2023Article
- A Review of Parental Vaccine Hesitancy for Human Papillomavirus in Japan.Journal of clinical medicine · 2023Review
- Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The availability of human papillomavirus (HPV) vaccines and screening tests has raised the possibility of globally eliminating cervical cancer, which is caused by HPV. Cervical cancer is a very common malignancy worldwide, especially among deprived women. High vaccination coverage is key to the containment and eventual elimination of the infection. Public HPV vaccination programmes in Italy and Denmark were swiftly established and are among the most successful worldwide. Still, in both countries, it has been challenging to achieve and maintain the recommended coverage of > 80% in girls. In a well-studied Italian region, vaccination coverage in girls at age 15 years (World Health Organization's gold standard) reached 76% in 2015 but decreased to 69% in 2018, likely due to work overload in public immunization centres. In Denmark, doubts about safety and efficacy of the HPV vaccine generated a decline in coverage among girls age 12-17, from 80% in 2013 down to 37% in 2015, when remedial actions made it rise again. Insights from these two countries are shared to illustrate the importance of monitoring coverage in a digital vaccine registry and promptly reacting to misinformation about vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.